{"news_desk": "Editorial", "print_page": "26", "section_name": "Opinion", "subsection_name": null, "byline": {"original": "By THE EDITORIAL BOARD", "person": [], "organization": "THE EDITORIAL BOARD"}, "abstract": "Editorial expresses concern about very high price of cholesterol drugs Praluent and Repatha, which could outweigh their benefits; notes that both drugs cost about $14,000 per month to take, and most patients prescribed drugs will need to take them for lifetime; underscores necessity for more competition to drive down prices, and for insurers to push pharmaceutical companies for larger discounts.", "type_of_material": "Editorial", "word_count": "507", "lead_paragraph": "Two new powerful drugs have been approved. The question is whether the benefits will outweigh the long-term costs.", "pub_date": "2015-09-08T00:00:00Z", "document_type": "article", "slideshow_credits": null, "headline": {"main": "The Price for Lowering Cholesterol", "content_kicker": "Editorial", "print_headline": "The Price for Lowering Cholesterol", "kicker": "Editorial"}, "snippet": "Two new powerful drugs have been approved. The question is whether the benefits will outweigh the long-term costs.", "multimedia": [{"height": 126, "url": "images/2015/09/08/opinion/08tue2web/08tue2web-thumbWide.jpg", "legacy": {"widewidth": "190", "wideheight": "126", "wide": "images/2015/09/08/opinion/08tue2web/08tue2web-thumbWide.jpg"}, "type": "image", "width": 190, "subtype": "wide"}, {"height": 427, "url": "images/2015/09/08/opinion/08tue2web/08tue2web-articleLarge.jpg", "legacy": {"xlargewidth": "600", "xlargeheight": "427", "xlarge": "images/2015/09/08/opinion/08tue2web/08tue2web-articleLarge.jpg"}, "type": "image", "width": 600, "subtype": "xlarge"}, {"height": 75, "url": "images/2015/09/08/opinion/08tue2web/08tue2web-thumbStandard.jpg", "legacy": {"thumbnailwidth": "75", "thumbnail": "images/2015/09/08/opinion/08tue2web/08tue2web-thumbStandard.jpg", "thumbnailheight": "75"}, "type": "image", "width": 75, "subtype": "thumbnail"}], "web_url": "http://www.nytimes.com/2015/09/08/opinion/the-price-for-lowering-cholesterol.html", "keywords": [{"rank": "1", "is_major": "Y", "value": "Editorials", "name": "subject"}, {"rank": "2", "is_major": "Y", "value": "Cholesterol", "name": "subject"}, {"rank": "3", "is_major": "N", "value": "Praluent (Drug)", "name": "subject"}, {"rank": "4", "is_major": "N", "value": "Repatha (Drug)", "name": "subject"}, {"rank": "5", "is_major": "N", "value": "Prices (Fares, Fees and Rates)", "name": "subject"}, {"rank": "6", "is_major": "N", "value": "Health Insurance and Managed Care", "name": "subject"}, {"rank": "7", "is_major": "N", "value": "Statins (Cholesterol-Lowering Drugs)", "name": "subject"}, {"rank": "8", "is_major": "Y", "value": "Drugs (Pharmaceuticals)", "name": "subject"}], "blog": [], "_id": "55ee8c6338f0d85bc57750e9", "source": "The New York Times"}